Pharmaxis Ltd (ASX:PXS)


right-arrow Created with Sketch. 0.002 (2.11%)
MCAP $52.14M
Last trade 13.24pm 28/01/2022 20mins delayed

Latest Announcements

27/01/2022PXSPharmaxis Ltd
10/01/2022 Price SensitivePSPXSPharmaxis Ltd
06/01/2022 Price SensitivePSPXSPharmaxis Ltd
24/12/2021PXSPharmaxis Ltd
23/12/2021PXSPharmaxis Ltd
23/12/2021PXSPharmaxis Ltd
22/12/2021PXSPharmaxis Ltd
22/12/2021PXSPharmaxis Ltd

Company Overview

Pharmaxis Ltd is a clinical stage drug development company engaged in developing drugs for inflammatory and fibrotic diseases and focused on myelofibrosis. The Company has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The Company's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.

PXS in the news

Pharmaxis (PXS) receives drug development grants from the Australian government, funding two…
Pharmaxis (PXS) has announced its oversubscribed share purchase plan (SPP) has raised…
Clinical stage drug development company Pharmaxis (PXS) has opened a $2 million share purchase…
Pharmaxis (PXS) grants Aptar Pharma the exclusive option to acquire worldwide rights…

Search Previous Announcements